Your session is about to expire
← Back to Search
Stent
ABRE Clinical Study of the Abre Venous Self-expanding Stent System
N/A
Waitlist Available
Led By Erin Murphy, MD
Research Sponsored by Medtronic Endovascular
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months, 12 months, 24 months, 36 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new type of stent to see if it is safe and effective for treating patients with a certain type of vein disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months, 12 months, 24 months, 36 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months, 12 months, 24 months, 36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Composite Major Adverse Events
Primary Patency
Secondary study objectives
Delayed Stent Migration
Device Success
EuroQol-5 Dimension (EQ-5D) Score
+12 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AbreExperimental Treatment1 Intervention
Abre Venous Self-expanding Stent System
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abre venous self-expanding stent system
2017
N/A
~260
Find a Location
Who is running the clinical trial?
Medtronic EndovascularLead Sponsor
69 Previous Clinical Trials
14,722 Total Patients Enrolled
Erin Murphy, MDPrincipal InvestigatorCarolinas Health Care System
2 Previous Clinical Trials
276 Total Patients Enrolled
Stephen Black, MDPrincipal InvestigatorGuy's and St Thomas' NHS Foundation Trust
2 Previous Clinical Trials
312 Total Patients Enrolled